

# Paula Peyrani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1896458/publications.pdf>

Version: 2024-02-01

8  
papers

145  
citations

1684188

5  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

144  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. <i>Vaccine</i> , 2019, 37, 3352-3361.	3.8	54
2	A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. <i>Vaccine</i> , 2021, 39, 5428-5435.	3.8	36
3	Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults. <i>Clinical Infectious Diseases</i> , 2021, 73, 1216-1222.	5.8	33
4	Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review. <i>Infectious Diseases and Therapy</i> , 2022, 11, 937-951.	4.0	10
5	A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years. <i>BMC Infectious Diseases</i> , 2020, 20, 426.	2.9	6
6	Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 1272-1279.	3.3	3
7	Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. <i>Vaccine</i> , 2022, 40, 1872-1878.	3.8	2
8	3. A Review of the Clinical Development of MenACWY-TT, a Quadrivalent Meningococcal Vaccine Conjugated to Tetanus Toxoid, in Adolescents. <i>Open Forum Infectious Diseases</i> , 2020, 7, S23-S24.	0.9	1